Neximmune announces formation of autoimmune and infectious diseases scientific advisory board

Gaithersburg, md., jan. 05, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced the formation of its autoimmune and infectious disease scientific advisory board (ai & id sab). the ai & id sab is comprised of distinguished academic and industry leaders in the fields of autoimmune and infectious diseases, translational research, immunology and t cell biology.
NEXI Ratings Summary
NEXI Quant Ranking